Dr Deborah O’Neil

CEO, NovaBiotics

A biotechnology entrepreneur and immunologist by training, Deborah has over two decades of experience in anti-infective drug discovery research and development. Deborah studied at University College London, then worked in postdoctoral positions in San Diego and Ghent before moving to Aberdeen (Rowett Research Institute, now part of the University of Aberdeen) where she founded NovaBiotics in 2004. The business has become a leading global biotechnology business, developing a portfolio of first-in-class anti-infective therapies addressing the urgent, unmet need for safe and effective antimicrobials including Nylexa for COVID-19. NovaBiotics is on the front line of the fight against antimicrobial resistance.